IGC Pharma (IGC) Non-Current Assets (2011 - 2026)
IGC Pharma (IGC) posted quarterly Non-Current Assets of $8.0 million for Q1 2026, up 37.38% year-over-year from $5.9 million in Q1 2025, and up 1.46% quarter-over-quarter from $7.9 million in Q4 2025.
IGC Pharma (IGC) Non-Current Assets (2011 - 2026) Analysis & Trends
IGC Pharma (IGC) has reported Non-Current Assets for 16 consecutive years, with $8.0 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Non-Current Assets rose 37.38% year-over-year to $8.0 million; the TTM figure through Mar 2026 stood at $8.0 million (up 37.38% YoY), while the FY2026 annual figure was $8.0 million, up 37.38% from the prior year.
- Non-Current Assets rose to $8.0 million in Q1 2026 per IGC's latest filing, from $7.9 million in the prior quarter.
- Across five years, Non-Current Assets topped out at $11.7 million in Q1 2022 and bottomed at $5.8 million in Q2 2025.
- Historically, Non-Current Assets has averaged $8.5 million across 5 years, with a median of $7.9 million in 2025.
- Annual changes were most pronounced in 2024 — Non-Current Assets slumped 42.15% — and 2026, when it surged 37.38%.
- IGC Pharma's Non-Current Assets stood at $10.7 million in 2022, then slipped by 28.37% to $7.7 million in 2023, then dropped by 21.48% to $6.0 million in 2024, then jumped by 31.44% to $7.9 million in 2025, then gained by 1.46% to $8.0 million in 2026.
- Business Quant data shows IGC's Non-Current Assets at $8.0 million in Q1 2026, $7.9 million in Q4 2025, and $7.7 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.61 Bn | 131.75 Bn | 2.84 Bn | 14.88 Bn |
| 2 | Regeneron Pharmaceuticals | 86.70 Bn | 78.71 Bn | 3.93 Bn | 23.28 Bn |
| 3 | Argenx Se | 65.28 Bn | 60.09 Bn | 1.37 Bn | 1.96 Bn |
| 4 | Moderna | 59.14 Bn | 54.00 Bn | 52.00 Mn | 5.15 Bn |
| 5 | BeOne Medicines | 42.13 Bn | 37.03 Bn | 1.53 Bn | 1.96 Bn |
| 6 | Alnylam Pharmaceuticals | 31.83 Bn | 28.52 Bn | 992.69 Mn | 938.60 Mn |
| 7 | BioNTech SE | 28.07 Bn | 9.68 Bn | 668.28 Mn | 6.80 Bn |
| 8 | Insmed | 27.54 Bn | 26.38 Bn | 358.27 Mn | 468.65 Mn |
| 9 | Royalty Pharma | 27.31 Bn | 26.47 Bn | - | 18.06 Bn |
| 10 | IGC Pharma | 28.20 Mn | 27.94 Mn | - | 8.04 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 8.04 Mn |
| Dec 31, 2025 | 7.92 Mn |
| Sep 30, 2025 | 7.74 Mn |
| Jun 30, 2025 | 5.79 Mn |
| Mar 31, 2025 | 5.85 Mn |
| Dec 31, 2024 | 6.03 Mn |
| Sep 30, 2024 | 6.12 Mn |
| Jun 30, 2024 | 6.19 Mn |
| Mar 31, 2024 | 6.20 Mn |
| Dec 31, 2023 | 7.68 Mn |
| Sep 30, 2023 | 10.39 Mn |
| Jun 30, 2023 | 10.60 Mn |
| Mar 31, 2023 | 10.71 Mn |
| Dec 31, 2022 | 10.72 Mn |
| Sep 30, 2022 | 10.76 Mn |
| Jun 30, 2022 | 11.44 Mn |
| Mar 31, 2022 | 11.72 Mn |
| Dec 31, 2021 | 12.05 Mn |
| Sep 30, 2021 | 12.13 Mn |
| Jun 30, 2021 | 12.25 Mn |